SCYNEXIS (STU:135) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


STU:135 SCYNEXIS Inc STU:135
43 GF Score
Price €4.84
GF Value €29.55
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is SCYNEXIS Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

SCYNEXIS's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:135 vs ETST, BGM, INCR: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SCYNEXIS Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Margin of Safety % (DCF Earnings Based) falls into.


STU:135
43GF Score
SCYNEXIS Inc STU:135
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SCYNEXIS (STU:135) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of €4.84 is trading 83.6% below its estimated GF Value™ of €29.55. GuruFocus considers SCYNEXIS to be Possible Value Trap.

Key valuation signals for STU:135:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €29.55 vs. price of €4.84 (83.6% below fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the STU:135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SCYNEXIS Business Description

Other Exchanges SCYX:USA0L49:UK
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
43GF Score

Get the complete analysis for STU:135

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.84
Price
€29.55
GF Value